
HAE Earnings
Haemonetics Corp
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of Haemonetics Corp(HAE) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Haemonetics Corp earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
FY2026Q1 | 2025-08-07 | Pre-Market | 1.01 | 1.10 | +8.91 | 304.61M | 321.39M | +5.51 | -26.58 | -31.07 |
FY2025Q4 | 2025-05-08 | Pre-Market | 1.22 | 1.24 | +1.64 | 329.38M | 330.60M | +0.37 | +5.85 | +7.61 |
FY2025Q3 | 2025-02-06 | Pre-Market | 1.19 | 1.19 | - | 352.88M | 348.54M | -1.23 | -11.58 | -13.94 |
FY2025Q1 | 2024-08-08 | Pre-Market | 1.03 | 1.02 | -0.97 | 335.04M | 336.17M | +0.34 | -10.84 | -14.63 |
FY2024Q4 | 2024-05-09 | - | 0.88 | 0.90 | +2.27 | 329.47M | 343.29M | +4.20 | -0.70 | +3.47 |
FY2024Q3 | 2024-02-08 | - | 0.97 | 1.04 | +7.22 | 320.77M | 336.25M | +4.82 | +1.30 | -7.61 |
FY2024Q2 | 2023-11-02 | - | 0.94 | 0.99 | +5.32 | 313.10M | 318.18M | +1.62 | -1.08 | -0.25 |
FY2024Q1 | 2023-08-08 | - | 0.76 | 1.05 | +38.16 | 292.69M | 311.33M | +6.37 | +1.46 | +4.67 |
- | 2023-05-11 | - | 0.68 | 0.77 | +13.24 | - | - | - | +3.30 | +2.94 |
- | 2023-02-07 | - | 0.79 | 0.85 | +7.59 | - | - | - | -5.91 | -6.95 |
HAE Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Haemonetics Corp reported performance for FY2026Q1, announced on 2025-08-07. The company achieved an EPS of 1.10, compared to analyst estimates of 1.01 by 8.91% . Revenue for the quarter reached 321.39M compared to expectations of 304.61M by 5.51% .
The stock price reacted with a -26.58% one-day change and a -31.07% five-day change following the earnings release. These movements reflect market reaction in Haemonetics Corp growth trajectory and strategic initiatives.
HAE Earnings Forecast
Looking ahead, Haemonetics Corp(HAE) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2026/Q2 project quarter revenue of 312.14M and an EPS of 1.11.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2026 have been Revise Downward by -0.28%, while EPS estimates have been Revise Downward by -0.06%. For the upcoming Q2 2026, revenue estimates have been adjusted Revise Downward by -2.19% . These revisions correlate with a -24.46% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Haemonetics Corp long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between HAE's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2026
Revise Downward

-0.28%
In Past 3 Month
EPS Estimates for FY2026
Revise Downward

-0.06%
In Past 3 Month
Revenue Estimates for Q2 2026
Revise Downward

-2.19%
In Past 3 Month
Stock Price
Go Down

-24.46%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2026
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2026:1.31B
--
EPS Estimate-Annual FY 2026:4.87
—
Stock Price52.23
HAE Revenue and EPS Performance: A Historical Perspective
Haemonetics Corp revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2026Q1 (2025-08-07,Pre-Market):
EPS: 1.10 (Actual) vs.1.01 (Estimate) (8.91%)
Revenue: 321.39M (Actual) vs. 304.61M (Estimate) (5.51%)
Price Reaction: -26.58%(1-Day), -31.07%(5-Day)
FY2025Q4 (2025-05-08,Pre-Market):
EPS: 1.24 (Actual) vs.1.22 (Estimate) (1.64%)
Revenue: 330.60M (Actual) vs. 329.38M (Estimate) (0.37%)
Price Reaction: 5.85%(1-Day), 7.61%(5-Day)
FY2025Q3 (2025-02-06,Pre-Market):
EPS: 1.19 (Actual) vs.1.19 (Estimate) (0.00%)
Revenue: 348.54M (Actual) vs. 352.88M (Estimate) (-1.23%)
Price Reaction: -11.58%(1-Day), -13.94%(5-Day)
Earnings Reaction
The chart below shows how HAE performed 10 days before and after its earnings report, based on data from the past quarters. Typically, HAE sees a +7.14% change in stock price 10 days leading up to the earnings, and a -2.71% change 10 days following the report. On the earnings day itself, the stock moves by -4.48%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2025, the stock changed -2.95% on the day following the earnings release and then changed by -6.11% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Haemonetics Corp (HAE) Q1 2026 Earnings Call Summary
Positive
2025-08-09
The earnings call highlights strong organic growth, optimistic guidance, and strategic initiatives to address market challenges. Despite temporary softness in certain segments, the company is taking proactive measures, such as hiring new leaders and reorganizing teams, which instill confidence. Strong gross margins and a positive outlook for plasma and hospital segments further support a positive sentiment. However, the lack of clear guidance on plasma collections and competitive pressures in vascular closure warrant cautious optimism. Considering the market cap, a positive stock price movement of 2% to 8% is anticipated.
Haemonetics Corp (HAE) Q3 2024 Earnings Call Summary
Neutral
2025-02-06
Despite strong financial performance, including record operating income and increased EPS, the outlook is tempered by challenges such as difficult market conditions in China, increased competition, and operational hurdles in new product launches. The reaffirmed and raised guidance for certain segments provides some optimism, but concerns over supply chain issues and the impact of the whole blood business divestiture balance the positives. The Q&A section revealed a cautious tone from analysts, with management providing optimistic yet vague responses. The market cap suggests a moderate reaction, leading to a neutral stock price prediction.
Haemonetics Corporation (HAE) Q2 2025 Earnings Call Summary
Neutral
2024-11-09
The earnings call presents a mixed picture: strong hospital revenue growth and improved margins contrast with declines in plasma and blood center revenues. The Q&A reveals uncertainty in product rollouts and regulatory challenges, which tempers optimism. The share buyback is positive, but economic headwinds and competitive pressures are concerning. Given the company's mid-cap status, the stock is likely to remain stable, leading to a neutral prediction.
Haemonetics Corporation (HAE) Q1 2025 Earnings Call Summary
Neutral
2024-08-08
The earnings call presented a mixed picture. Strong hospital revenue growth and strategic acquisitions are positive, but plasma and blood center revenues declined, and there are concerns over increased expenses and competition. The Q&A highlighted robust demand and some positive product feedback, but management's vague responses on key metrics raise uncertainties. Despite some positive indicators, the overall financial health and competitive pressures suggest a neutral outlook, especially given the market cap of $4.2 billion, which may moderate stock volatility.
People Also Watch

FROG
Jfrog Ltd
41.060
USD
-2.61%

SKT
Tanger Inc
32.430
USD
+2.59%

RUM
Rumble Inc
7.920
USD
-2.46%

ALIT
Alight Inc
3.830
USD
-0.26%

GFF
Griffon Corp
72.830
USD
+4.46%

IAC
IAC Inc
33.950
USD
-0.35%

ASO
Academy Sports and Outdoors Inc
52.020
USD
+4.06%

KFY
Korn Ferry
71.750
USD
+1.64%

ATGE
Adtalem Global Education Inc
126.990
USD
+5.63%

SHC
Sotera Health Co
14.860
USD
+5.69%
FAQ

What were the key highlights of HAE’s latest earnings report for FY2026Q1?
HAE reported its FY2026Q1 earnings on 2025-08-07, showcasing a revenue of 321.39M against an estimate of 304.61M, resulting in a 5.51% surprise. The EPS was 1.1, surpassing the expected 1.01 by 8.91% . The stock experienced a -26.58% price change on the earnings day and a -31.07% change over the next five days, reflecting market reactions to the results.

How did HAE’s stock price react after the FY2026Q1 earnings release?

What are the revenue and EPS estimates for HAE for 2026/Q2?

How does HAE’s stock price correlate with earnings forecast revisions?

What should investors expect from HAE’s next earnings report?
